ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
62,981.31
0.15%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Acrivon Therapeutics Inc (ACRV)

  7. Acrivon Therapeutics Inc (ACRV) Noticias

ACRV Acrivon Therapeutics Inc

9.59
1.13 (13.36%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Acrivon Therapeutics Inc ACRV NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
1.13 13.36% 9.59 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
8.51 8.31 10.29 9.59 8.46
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
24/4/202415:01GLOBEAcrivon Therapeutics Reports Initial Positive Clinical Data..
16/4/202419:01GLOBEAcrivon Therapeutics to Host Corporate R&D Event..
10/4/202407:00GLOBEAcrivon Therapeutics Presents Data at AACR Annual Meeting..
09/4/202406:00GLOBEAcrivon Therapeutics Announces $130 Million Private..
28/3/202407:00GLOBEAcrivon Therapeutics Reports Fourth Quarter and Full Year..
06/3/202415:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202415:29EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/3/202415:30GLOBEAcrivon Therapeutics to Present Data at AACR Annual Meeting..
04/3/202407:15EDGAR2Form 8-K - Current report
04/3/202407:00GLOBEAcrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA,..
27/2/202407:00GLOBEAcrivon Therapeutics to Participate in a Panel Discussion at..
16/2/202416:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202414:40EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202407:27EDGAR2Form 8-K - Current report
08/2/202407:00GLOBEAcrivon Therapeutics Appoints Seasoned Industry Executive..
06/2/202407:00GLOBEAcrivon Therapeutics to Present at the Oppenheimer 34th..
19/1/202415:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202415:00GLOBEAcrivon Therapeutics Announces Inducement Grants Under..
08/1/202406:28EDGAR2Form 8-K - Current report
04/1/202407:00GLOBEAcrivon Therapeutics to Present at the 42nd Annual J.P...
17/12/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
08/12/202315:21EDGAR2Form 8-K - Current report
01/12/202315:35EDGAR2Form S-3 - Registration statement under Securities Act of..
28/11/202307:58DJNAcrivon Therapeutics Gets FDA's Breakthrough Designation for..
28/11/202307:00GLOBEAcrivon Therapeutics Announces FDA has Granted Breakthrough..
21/11/202307:00GLOBEAcrivon Therapeutics Announces Inducement Grant Under Nasdaq..
16/11/202318:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202318:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202318:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202318:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202318:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202318:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202308:12EDGAR2Form 8-K - Current report
09/11/202307:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202307:01GLOBEAcrivon Therapeutics Reports Third Quarter 2023 Financial..
19/10/202318:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/10/202307:00GLOBEAcrivon Therapeutics Presents Data Demonstrating..
28/9/202318:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/9/202318:13EDGAR2Form 3 - Initial statement of beneficial ownership of..
28/9/202315:05GLOBEAcrivon Therapeutics Announces Inducement Grants Under..
19/9/202315:32GLOBEAcrivon Therapeutics to Highlight its ACR-368 OncoSignature..
05/9/202316:23EDGAR2Form 8-K - Current report
05/9/202315:05GLOBEAcrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1..
30/8/202307:00GLOBEAcrivon Therapeutics to Participate in Two Investor..
23/8/202315:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
ACRV
Acrivon Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados